Loxapine

This classification denotes an antipsychotic agent with the molecular formula C18H18ClN3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier LER583670J, chemically known as 1,4-butanedioic acid (succinic acid) but generally known as loxapine, which bears US NIH Compound Identifier 1110. European Medicines Agency schedules Loxapine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08607MIG. The term LOXAPINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 24, No. 11 1970, List 10). World Health Organization schedules loxapine in its Anatomical Therapeutic Chemical (ATC) Classification. LOXAPINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule loxapine under HS 29349990 and SITC 51579. As of Q4 2014, LOXAPINE remains the US FDA Preferred Term for this commodity. Loxapine bears US NLM identifiers UMLS ID C0024056 and NCI Concept Code C61816. SMILES: OC(=O)CCC(=O)O.